Roche Diagnostics growth remains muted amid China headwinds July 23, 2026Posted inMedical Technology Roche’s Diagnostics division continues to battle growth headwinds, notching a 3% increase in sales. Post navigation Previous Post Australian biopharma Clinuvel to shed up to 20% of workforce in move to USNext PostLilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
